Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance - PubMed (original) (raw)
Review
Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance
Hilal S Khalil et al. J Biotechnol. 2015.
Free article
Abstract
Seliciclib (R-Roscovitine) was identified as an inhibitor of CDKs and has undergone drug development and clinical testing as an anticancer agent. In this review, the authors describe the discovery of Seliciclib and give a brief summary of the biology of the CDKs Seliciclib inhibits. An overview of the published in vitro and in vivo work supporting the development as an anti-cancer agent, from in vitro experiments to animal model studies ending with a summary of the clinical trial results and trials underway is presented. In addition some potential non-oncology applications are explored and the potential mode of action of Seliciclib in these areas is described. Finally the authors argue that optimisation of the therapeutic effects of kinase inhibitors such as Seliciclib could be enhanced using a systems biology approach involving mathematical modelling of the molecular pathways regulating cell growth and division.
Keywords: CDK; Seliciclib; Systems biology.
Crown Copyright © 2015. Published by Elsevier B.V. All rights reserved.
Similar articles
- Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus.
Zoja C, Casiraghi F, Conti S, Corna D, Rottoli D, Cavinato RA, Remuzzi G, Benigni A. Zoja C, et al. Arthritis Rheum. 2007 May;56(5):1629-37. doi: 10.1002/art.22593. Arthritis Rheum. 2007. PMID: 17469145 - Recent progress in the discovery and development of cyclin-dependent kinase inhibitors.
Fischer PM, Gianella-Borradori A. Fischer PM, et al. Expert Opin Investig Drugs. 2005 Apr;14(4):457-77. doi: 10.1517/13543784.14.4.457. Expert Opin Investig Drugs. 2005. PMID: 15882121 Review. - The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.
Coley HM, Shotton CF, Kokkinos MI, Thomas H. Coley HM, et al. Gynecol Oncol. 2007 May;105(2):462-9. doi: 10.1016/j.ygyno.2007.01.004. Epub 2007 Feb 14. Gynecol Oncol. 2007. PMID: 17300833 - Seliciclib in malignancies.
Aldoss IT, Tashi T, Ganti AK. Aldoss IT, et al. Expert Opin Investig Drugs. 2009 Dec;18(12):1957-65. doi: 10.1517/13543780903418445. Expert Opin Investig Drugs. 2009. PMID: 19938906 - Cyclin-dependent kinase modulators and cancer therapy.
Gallorini M, Cataldi A, di Giacomo V. Gallorini M, et al. BioDrugs. 2012 Dec 1;26(6):377-91. doi: 10.1007/BF03261895. BioDrugs. 2012. PMID: 22928661 Review.
Cited by
- Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments.
Xiao L, Liu Y, Chen H, Shen L. Xiao L, et al. Cancer Biol Ther. 2023 Dec 31;24(1):2219470. doi: 10.1080/15384047.2023.2219470. Cancer Biol Ther. 2023. PMID: 37272701 Free PMC article. Review. - Quantitative Chemotherapeutic Profiling of Gynecologic Cancer Cell Lines Using Approved Drugs and Bioactive Compounds.
Gorshkov K, Sima N, Sun W, Lu B, Huang W, Travers J, Klumpp-Thomas C, Michael SG, Xu T, Huang R, Lee EM, Cheng X, Zheng W. Gorshkov K, et al. Transl Oncol. 2019 Mar;12(3):441-452. doi: 10.1016/j.tranon.2018.11.016. Epub 2018 Dec 18. Transl Oncol. 2019. PMID: 30576957 Free PMC article. - Therapeutic targeting of transcriptional cyclin-dependent kinases.
Galbraith MD, Bender H, Espinosa JM. Galbraith MD, et al. Transcription. 2019 Apr;10(2):118-136. doi: 10.1080/21541264.2018.1539615. Epub 2018 Nov 9. Transcription. 2019. PMID: 30409083 Free PMC article. Review. - Tau PET imaging in neurodegenerative tauopathies-still a challenge.
Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, Nordberg A. Leuzy A, et al. Mol Psychiatry. 2019 Aug;24(8):1112-1134. doi: 10.1038/s41380-018-0342-8. Epub 2019 Jan 11. Mol Psychiatry. 2019. PMID: 30635637 Free PMC article. Review. - Molecular and Therapeutic Targets for Amyloid-beta Plaques in Alzheimer's Disease: A Review Study.
Thomas J, Wilson S. Thomas J, et al. Basic Clin Neurosci. 2024 Jan-Feb;15(1):1-26. doi: 10.32598/bcn.2021.3522.1. Epub 2024 Jan 1. Basic Clin Neurosci. 2024. PMID: 39291090 Free PMC article. Review.